Oral presentation of investigator-initiated
Phase 2 study evaluating ZYNLONTA® (loncastuximab
tesirine-lpyl) in combination with rituximab in patients with r/r
follicular lymphoma
Poster presentation of first interim futility
analysis of ongoing investigator-initiated Phase 2 clinical trial
studying ZYNLONTA as treatment for r/r marginal zone
lymphoma
LAUSANNE, Switzerland, Nov. 5, 2024
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a
commercial-stage global leader and pioneer in the field of antibody
drug conjugates (ADCs), today announced independent,
investigator-initiated study abstracts on
ZYNLONTA® (loncastuximab tesirine-lpyl) have been
accepted for presentation at the 66th American
Society of Hematology (ASH) Annual Meeting, which will be held
in San Diego, California from
December 7-10, 2024.
"Data from the abstract on the Phase 2 study of ZYNLONTA
combined with rituximab in patients with high-risk relapsed or
refractory follicular lymphoma demonstrated a robust response among
the 35 evaluable patients, with an overall response rate at
week 12 of 97.1%," said Mohamed
Zaki, MD, PhD, Chief Medical Officer of ADC
Therapeutics. "All complete metabolic responses were
maintained, with 4 of the 10 partial metabolic responses improving
at week 21 for a best complete metabolic response rate of
80%."
"For relapsed or refractory marginal zone lymphoma, the abstract
provides an update on ZYNLONTA as a single-agent treatment. As
of the abstract submission date, the overall response rate was 85%
with a complete response rate of 75% among the 20 evaluable
patients," continued Dr. Zaki. "In both studies, safety was
consistent with the known ZYNLONTA profile. We look forward to
further updates at ASH."
Details of the investigator-initiated study oral
presentation:
Title: Loncastuximab Tesirine with Rituximab Induces
Robust and Durable Complete Metabolic Responses in High-Risk
Relapsed/Refractory Follicular Lymphoma
Abstract: 337
Session Title: 623. Mantle Cell, Follicular,
Waldenstrom's and Other Indolent B Cell Lymphomas: Clinical and
Epidemiological: Novel Treatment Strategies and New Data on Old
Standards for Follicular Lymphoma
Session Date and Time: Saturday,
December 7, 2024; 4:00-5:30 p.m.
PT
Presentation Time: 4:00 p.m.
PT
Presenter: Juan Pablo Alderuccio, MD
Location: Marriott Marquis San Diego Marina, Marriott Grand
Ballroom 11-13
Details of the investigator-initiated study poster
presentation:
Title: Limited Duration Loncastuximab Tesirine
Induces a High Rate of Complete Responses in Patients with
Relapsed/Refractory Marginal Zone Lymphoma - Report of First
Planned Interim Futility Analysis of a Multicenter Phase II
Study
Abstract: 3032
Session Title: 623. Mantle Cell, Follicular,
Waldenstrom's and Other Indolent B Cell Lymphomas: Clinical and
Epidemiological: Poster II
Hall View Times: Sunday, December 8,
2024; 9:00 a.m. - 8:00 p.m.
PT
Presentation Date and Time: Sunday,
December 8, 2024; 6:00-8:00 p.m.
PT
Location: San Diego
Convention Center, Halls G-H
The abstracts are available through the ASH online meeting
program.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in
London and New Jersey. For more information, please visit
the Company website at adctherapeutics.com and follow us on
LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
In some cases you can identify forward-looking statements by
terminology such as "may", "will", "should", "would", "expect",
"intend", "plan", "anticipate", "believe", "estimate", "predict",
"potential", "seem", "seek", "future", "continue", or "appear" or
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: whether the interim data presented
in the abstract from the University of
Miami's investigator-initiated trials studying
ZYNLONTA® in FL and MZL are predictive of future
outcomes and the timing and future results for the same ongoing
trials, the potential regulatory and/or compendia strategy and the
future opportunity for ZYNLONTA® in FL and MZL; the
expected cash runway into mid-2026 the Company's ability to grow
ZYNLONTA® revenue in the
United States; the ability of our partners to commercialize
ZYNLONTA® in foreign markets, the timing and amount of
future revenue and payments to us from such partnerships and their
ability to obtain regulatory approval for ZYNLONTA® in
foreign jurisdictions; the timing and results of the Company's or
its partners' research and development projects or clinical trials
including LOTIS 5 and 7, ADCT 601 and
602 as well as early research in certain solid tumors with
different targets, linkers and payloads; the timing and outcome of
regulatory submissions for the Company's products or product
candidates; actions by the FDA or foreign regulatory authorities;
projected revenue and expenses; the Company's indebtedness,
including Healthcare Royalty Management and Blue Owl and Oaktree
facilities, and the restrictions imposed on the Company's
activities by such indebtedness, the ability to comply with the
terms of the various agreements and repay such indebtedness and the
significant cash required to service such indebtedness; and the
Company's ability to obtain financial and other resources for its
research, development, clinical, and commercial activities.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K and in the
Company's other periodic and current reports and filings with the
U.S. Securities and Exchange Commission. These statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this document.
CONTACTS:
Investors
Marcy
Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download
multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-investigator-initiated-study-abstracts-accepted-for-presentation-at-the-66th-ash-annual-meeting-302296637.html
SOURCE ADC Therapeutics SA